QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:MDXH

MDxHealth (MDXH) Stock Forecast, Price & News

$4.00
+0.01 (+0.25%)
(As of 06/7/2023 ET)
Compare
Today's Range
$3.97
$4.18
50-Day Range
$3.07
$4.20
52-Week Range
$2.47
$9.49
Volume
187,206 shs
Average Volume
231,880 shs
Market Capitalization
$65.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

MDxHealth MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.5% Upside
$10.50 Price Target
Short Interest
Healthy
0.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of MDxHealth in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.09) to ($1.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

608th out of 981 stocks

Medical Laboratories Industry

16th out of 22 stocks


MDXH stock logo

About MDxHealth (NASDAQ:MDXH) Stock

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Receive MDXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter.

MDXH Stock News Headlines

TD Cowen Initiates Coverage on MDxHealth (NASDAQ:MDXH)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
mdxhealth: MDxHealth Reports Q1-2023 Results
MDxHealth Reports Q1-2023 Results
MDxHealth earnings preview: what Wall Street is expecting
Short Volatility Alert: Mdxhealth
Foundational LCD Covers Select mdx for Prostate Cancer
Contrasting MDxHealth (MDXH) and Its Competitors
Contrasting MDxHealth (MDXH) & Its Competitors
Head to Head Analysis: MDxHealth (MDXH) vs. The Competition
See More Headlines

MDXH Price History

MDXH Company Calendar

Today
6/07/2023
Next Earnings (Estimated)
8/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXH
Fax
N/A
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+162.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-44,040,000.00
Net Margins
-104.02%
Pretax Margin
-118.86%

Debt

Sales & Book Value

Annual Sales
$37.05 million
Book Value
$0.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$65.16 million
Optionable
Not Optionable
Beta
0.25

Key Executives

  • Mr. Michael K. McGarrity (Age 60)
    CEO & Exec. Director
    Comp: $571.96k
  • Mr. Ron Kalfus (Age 49)
    Chief Financial Officer
  • Mr. Joseph Sollee (Age 58)
    Exec. VP of Corp. Devel. & Gen. Counsel
  • Mr. John A. Bellano (Age 54)
    Chief Commercial Officer
  • Ms. Miriam Reyes (Age 50)
    Exec. VP of Operations
  • Dr. Wim Van Criekinge (Age 51)
    Chief Scientific Officer













MDXH Stock - Frequently Asked Questions

Should I buy or sell MDxHealth stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MDxHealth in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXH shares.
View MDXH analyst ratings
or view top-rated stocks.

What is MDxHealth's stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year price targets for MDxHealth's stock. Their MDXH share price forecasts range from $7.00 to $18.00. On average, they anticipate the company's share price to reach $10.50 in the next year. This suggests a possible upside of 162.5% from the stock's current price.
View analysts price targets for MDXH
or view top-rated stocks among Wall Street analysts.

How have MDXH shares performed in 2023?

MDxHealth's stock was trading at $6.61 at the beginning of the year. Since then, MDXH shares have decreased by 39.5% and is now trading at $4.00.
View the best growth stocks for 2023 here
.

When is MDxHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023.
View our MDXH earnings forecast
.

When did MDxHealth IPO?

(MDXH) raised $45 million in an IPO on Thursday, November 4th 2021. The company issued 3,750,000 shares at $12.00 per share.

What is MDxHealth's stock symbol?

MDxHealth trades on the NASDAQ under the ticker symbol "MDXH."

Who are MDxHealth's major shareholders?

MDxHealth's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (3.68%), Hood River Capital Management LLC (3.55%), Ally Bridge Group NY LLC (3.07%), Element Capital Management LLC (2.63%), Perkins Capital Management Inc. (2.51%) and Sei Investments Co. (1.03%).
View institutional ownership trends
.

How do I buy shares of MDxHealth?

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MDxHealth's stock price today?

One share of MDXH stock can currently be purchased for approximately $4.00.

How much money does MDxHealth make?

MDxHealth (NASDAQ:MDXH) has a market capitalization of $65.16 million and generates $37.05 million in revenue each year. The company earns $-44,040,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does MDxHealth have?

The company employs 252 workers across the globe.

How can I contact MDxHealth?

MDxHealth's mailing address is CAP Business Center, Herstal, Liege 4040. The official website for the company is mdxhealth.com. The company can be reached via phone at 324-364-2070 or via email at ir@mdxhealth.com.

This page (NASDAQ:MDXH) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -